CN Patent

CN102453021A — 来那度胺的新晶型及其制备方法

Assigned to Chongqing Pharmaceutical Research Institute Co Ltd · Expires 2012-05-16 · 14y expired

What this patent protects

本发明涉及来那度胺的一种新晶型及其制备方法，所述的新晶型为来那度胺晶型I，以及含有这种新晶型来那度胺晶型I的药物组合物，来那度胺晶型I在制造治疗慢性骨髓瘤或有5q缺失的骨髓增生异常综合症的药物中的用途。来那度胺晶型I稳定适于制剂的制造。

USPTO Abstract

本发明涉及来那度胺的一种新晶型及其制备方法，所述的新晶型为来那度胺晶型I，以及含有这种新晶型来那度胺晶型I的药物组合物，来那度胺晶型I在制造治疗慢性骨髓瘤或有5q缺失的骨髓增生异常综合症的药物中的用途。来那度胺晶型I稳定适于制剂的制造。

Drugs covered by this patent

Patent Metadata

Patent number
CN102453021A
Jurisdiction
CN
Classification
—
Expires
2012-05-16
Drug substance claim
No
Drug product claim
No
Assignee
Chongqing Pharmaceutical Research Institute Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.